Drugs /

nis793

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Anti-TGF-beta monoclonal antibody NIS793 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.

Clinical Trials

View Clinical Trials for nis793

Nis793 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating nis793, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

Deficient DNA Mismatch Repair (dMMR), ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for nis793 clinical trials.

Breast carcinoma, colorectal carcinoma, and malignant solid tumor are the most common diseases being investigated in nis793 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nis793
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Nis793
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nis793 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-tgf-beta monoclonal antibody nis793
Drug Target(s) [2]:
TGFB1
NCIT ID [1]:
C132250

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.